Human Enhancement in Sports

  • Andy MiahEmail author
Reference work entry


This chapter examines the range of sciences and technologies that converge around sports and the implications of this for issues of fairness and ethics. First, it outlines some of the recent scientific developments that speak to the convergence of disciplines pertinent to sports enhancements. Second, it considers the consequences of convergence within sport, inquiring into the practical ethical issues it provokes. Finally, it explores examples of technological effect in sport, which, collectively, articulate how far ranging are the many ways in which innovation converges on sports. In so doing, it provides a taxonomy of innovations which reveal the complexity of technological change in sports and the challenge of isolating artifice from nature.


Sport Prosthetics Gene doping Anti-doping Transhumanism 


  1. American Academy of Pediatrics (2005) Policy statement: use of performance-enhancing substances. Pediatrics 115:1103–1106CrossRefGoogle Scholar
  2. Australia Law Reform Commission (2003) ALRC 96: essentially yoursGoogle Scholar
  3. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL (1998) Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 95:15603–15607CrossRefGoogle Scholar
  4. Bjerklie D (1993) High-tech olympians. Technol Rev 96:22–30Google Scholar
  5. Brody H (2000) An overview of racket technology. In: Haake SA, Coe AO (eds) Tennis science and technology. Blackwell, London, pp 43–48Google Scholar
  6. Brull D, Dhamrait S, Myerson s, Erdmann J, Regitz-Zagrosek V, World M, ... Montgomery H (2001) Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. The Lancet, 358:1155–1156Google Scholar
  7. Busch A (1998) Design for sports: the cult of performance. Thames & Hudson, LondonGoogle Scholar
  8. Denham BE (1999a) Building the agenda and adjusting the frame: how the dramatic revelations of lylle alzado impacted mainstream press coverage of anabolic steroid use. Sociol Sport J, 16, 1–15Google Scholar
  9. Denham BE (1999b) On drugs in sports in the aftermath of Flo-Jo’s death, Big Mac’s attack. Journal of Sport and Social Issues, 23(3), 362–367Google Scholar
  10. Donati A (2005). Criminality in the International Doping Trade. World Anti-Doping Agency, Presentation. Available: Accessed 25 July 2015
  11. Fotheringham W (1996) Cycling: hour of pain, shame or glory. The Guardian, London, 14Google Scholar
  12. Fraleigh WP (1984) Performance-enhancing drugs in sport: the ethical issue. J Philos Sport XI:23–29CrossRefGoogle Scholar
  13. Gardner R (1989) On performance-enhancing substances and the unfair advantage argument. J Philos Sport XVI:59–73CrossRefGoogle Scholar
  14. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, Trent RJ (1998) Elite endurance athletes and the ACE I allele – the role of genes in athletic performance. Hum Genet 1031:48–50CrossRefGoogle Scholar
  15. Gelberg JN (1995) The lethal weapon: how the plastic football helmet transformed the game of football, 1939–1994. Bull Sci Technol Soc 155–6:302–309Google Scholar
  16. Goldspink G (2001) Gene expression in skeletal muscle. Biochem Soc Trans 30:285–290CrossRefGoogle Scholar
  17. Hoberman JM (1992) Mortal engines: the science of performance and the dehumanization of sport. The Free Press, New York, Reprinted 2001, the Blackburn PressGoogle Scholar
  18. Hon O, Coumans B (2007) The continuing story of nutritional supplements and doping infractions. Br J Sports Med 41:800–805CrossRefGoogle Scholar
  19. Hummel RL, Foster GS (1986) A sporting chance: relationships between technological change & concepts of fair play in fishing. J Leis Res 181:40–52Google Scholar
  20. Inizan F (1994) Masters and slaves of time. Olympic Rev 320:306–310Google Scholar
  21. Lamsam C, Fu FH, Robbins PD, Evans CH (1997) Gene therapy in sports medicine. Sports Med 252:73–77Google Scholar
  22. Levine BD (2006) Should “Artificial” high altitude environments be considered doping? Scand J Med Sci Sports 16(5):297–301CrossRefGoogle Scholar
  23. Lin J, Wu H, Tarr PT, Zhang C, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelmann BM (2002) Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature 418:797–801CrossRefGoogle Scholar
  24. Loland S, Murray TH (2007) The ethics of the use of technologically constructed high-altitude environments to enhance performances in sport. Scand J Med Sci Sports 17:193–195CrossRefGoogle Scholar
  25. Magdalinski T (2000) Performance technologies: drugs and Fastskin at the Sydney 2000 Olympics. Media Int Australia 97:59–69Google Scholar
  26. Martinek V, Fu FH et al (2000) Gene therapy and tissue engineering in sports medicine. Phys Sportsmed 282.
  27. Miah A (2000a) Chapter 27: Climbing upwards of climbing backwards? The technological metamorphoses of climbing and mountaineering. In: Messenger N, Patterson W, Brook D (eds) The science of climbing and mountaineering. Human Kinetics, LondonGoogle Scholar
  28. Miah A (2000b) The engineered athlete: human rights in the genetic revolution. Culture Sport Soc 33:25–40CrossRefGoogle Scholar
  29. Miah A (2000c) “New balls please”: tennis, technology, and the changing game. In: Haake SA, Coe AO (eds) Tennis science and technology. Blackwell, London, pp 285–292Google Scholar
  30. Miah A (2004) Genetically modified athletes: biomedical ethics, gene doping and sport. Routledge, London/New YorkGoogle Scholar
  31. Montgomery H, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL, Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M, Talmud PJ, Humphries SE (1998) Human gene for physical performance. Nature 393:221–222CrossRefGoogle Scholar
  32. Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, Hajnal J, Hemingway H, Mercer D, Jarman P, Marshall R, Prasad K, Rayson M, Saeed N, Talmud P, Thomas L, Jubb M, World M, Humphries S (1999) Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 353(13):541–545CrossRefGoogle Scholar
  33. Munthe C (2000) Selected champions: making winners in the age of genetic technology. In: Tännsjö T, Tamburrini C (eds) Values in sport: elitism, nationalism, gender equality, and the scientific manufacture of winners. E & F.N. Spon, London/New York, pp 217–231Google Scholar
  34. Murray TH (1983) The coercive power of drugs in sports. Hastings Cent Rep 13(4):24–30CrossRefGoogle Scholar
  35. Murray TH (1984) Drugs, sports, and ethics. In: Murray TH, Gaylin W, Macklin R (eds) Feeling good and doing better. Humana Press, T. Clifton, pp 107–126CrossRefGoogle Scholar
  36. Murray TH (1986a) Guest editorial: drug testing and moral responsibility. Phys Sportsmed 1411:47–48Google Scholar
  37. Murray TH (1986b) Guest editorial: human growth hormone in sports: no. Phys Sportsmed 145:29Google Scholar
  38. Parens E (ed) (1998) Enhancing human traits: ethical and social implications, Hastings center studies in ethics. Georgetown University Press, Washington, DCGoogle Scholar
  39. Science and Technology Select Committee (2006) New inquiry: human enhancement technologies in sport. Select Committee for Science and Technology, British Government, LondonGoogle Scholar
  40. Sekera MH, Ahrens BD et al (2005) Another designer steroid: discovery, synthesis, and detection of “madol” in urine. Rapid Commun Mass Spectom 19:781–784CrossRefGoogle Scholar
  41. Svensson EC, Black HB, Dugger DL, Tripathy SK, Goldwasser E, Hao Z, Chu L, Leiden JM (1997) Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 815:1797–1806CrossRefGoogle Scholar
  42. Sweney M (2015) ‘Beach body ready’ ad banned from returning to tube, watchdog rules. The Guardian. Available Online Accessed 1 May 2015
  43. Templeton S.-K (2006) Footballers use babies for “repair kits.” The Sunday Times. London. Retrieved from
  44. Tenner E (1996) Why things bite back: predicting the problems of progress. Fourth Estate, LondonGoogle Scholar
  45. The U.S. President’s Council on Bioethics (2002a) Session 4: enhancement 2: potential for genetic enhancements in sports. The President’s Council on Bioethics, Washington, DC. Hypertext document, available at
  46. The U.S. President’s Council on Bioethics (2002b) Sixth meeting: session 7: enhancement 5: genetic enhancement of muscle. The President’s Council on Bioethics, Washington, DC. Hypertext document, available at
  47. The U.S. President’s Council on Bioethics (2003) Beyond therapy: biotechnology and the pursuit of happiness. President’s Council on Bioethics, Washington, DCGoogle Scholar
  48. World Anti-Doping Agency (2005) The Stockholm declaration. World Anti-Doping Agency.Google Scholar
  49. World Anti-Doping Agency (2009) World Anti-Doping Code, Montreal WADA.Google Scholar
  50. World Anti-Doping Agency (2015) World anti-doping code. Prohibited classes of substances and prohibited methodsGoogle Scholar
  51. World Anti-Doping Agency (2014) World Anti-Doping Code, WADA. Available at: Accessed 25 July 2015

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Chair in Science Communication and Future Media, School of Environment and Life SciencesUniversity of SalfordManchesterUK

Personalised recommendations